- Home
- AKRO
as of 12-08-2025 3:46pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 4.5B | IPO Year: | 2019 |
| Target Price: | $73.56 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.34 - $58.40 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered AKRO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
President and CEO
Avg Cost/Share
$53.98
Shares
30,000
Total Value
$1,619,340.00
Owned After
526,114
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$46.42
Shares
12,500
Total Value
$576,001.43
Owned After
167,608
Chief Operating Officer
Avg Cost/Share
$47.81
Shares
12,500
Total Value
$596,978.34
Owned After
201,099
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cheng Andrew | AKRO | President and CEO | Oct 10, 2025 | Sell | $53.98 | 30,000 | $1,619,340.00 | 526,114 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Oct 7, 2025 | Sell | $46.42 | 12,500 | $576,001.43 | 167,608 | |
| Young Jonathan | AKRO | Chief Operating Officer | Oct 1, 2025 | Sell | $47.81 | 12,500 | $596,978.34 | 201,099 |
Compare AKRO vs Leading Stocks
See how AKRO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.